Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe by Koletzko, Sibylle et al.
HELICOBACTER PYLORI
Prospective multicentre study on antibiotic resistance
of Helicobacter pylori strains obtained from children
living in Europe
S Koletzko, F Richy, P Bontems, J Crone, N Kalach, M L Monteiro, F Gottrand,
D Celinska-Cedro, E Roma-Giannikou, G Orderda, S Kolacek, P Urruzuno, M J
Martı´nez-Go´mez, T Casswall, M Ashorn, H Bodanszky, F Me´graud, on behalf of the
European Paediatric Task Force on Helicobacter pylori
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Professor S Koletzko, Dr v
Haunersches Kinderspital,
Ludwig Maximilians
University, Lindwurmstr 4,
D-80337 Munich,
Germany; Sibylle.
Koletzko@
med.uni-muenchen.de
Revised 5 March 2006
Accepted 16 March 2006
Published Online First
7 April 2006
. . . . . . . . . . . . . . . . . . . . . . .
Gut 2006;55:1711–1716. doi: 10.1136/gut.2006.091272
Aim: To prospectively assess the antibacterial resistance rate in Helicobacter pylori strains obtained from
symptomatic children in Europe.
Methods: During a 4-year period, 17 paediatric centres from 14 European countries reported
prospectively on patients infected with H pylori, for whom antibiotic susceptibility was tested.
Results: A total of 1233 patients were reported from Northern (3%), Western (70%), Eastern (9%) and
Southern Europe (18%); 41% originated from outside Europe as indicated by mother’s birth-country; 13%
were ,6 years of age, 43% 6–11 years of age and 44% .11 years of age. Testing was carried out
before the first treatment (group A, n = 1037), and after treatment failure (group B, n = 196). Overall
resistance to clarithromycin was detected in 24% (mean, A: 20%, B: 42%). The primary clarithromycin
resistance rate was higher in boys (odds ratio (OR) 1.58; 1.12 to 2.24, p = 0.01), in children ,6 years
compared with .12 years (OR 1.82, 1.10 to 3.03, p = 0.020) and in patients living in Southern Europe
compared with those living in Northern Europe (OR 2.25; 1.52 to 3.30, p,0.001). Overall resistance rate
to metronidazole was 25% (A: 23%, B: 35%) and higher in children born outside Europe (A: adjusted. OR
2.42, 95% CI: 1.61 to 3.66, p,0.001). Resistance to both antibiotics occurred in 6.9% (A: 5.3%, B:
15.3%). Resistance to amoxicillin was exceptional (0.6%). Children with peptic ulcer disease (80/1180,
6.8%) were older than patients without ulcer (p = 0.001).
Conclusion: The primary resistance rate of H pylori strains obtained from unselected children in Europe is
high. The use of antibiotics for other indications seems to be the major risk factor for development of
primary resistance.
T
riple treatment including a proton pump inhibitor plus
two antibiotics (chosen between clarithromycin, metro-
nidazole and amoxicillin) has been recommended to
treat children with Helicobacter pylori infection.1 2 The main
factors for treatment failure are bacterial resistance to the
antibiotics used in the regimen and low compliance with
drugs.3 4 Treatment failure is highly predictive if (1) the H
pylori strain is resistant to macrolides and (2) clarithromycin
is part of the regimen.5–7 Resistance to metronidazole also
affects the efficacy of the treatment if metronidazole is used
as part of triple treatment, but to a much lesser extent, in
both children8 and adults.9 10
In the Western and Northern European countries, most of
the children infected with H pylori are from immigrant
families originating from African or Asian countries where
the primary resistance to metronidazole is high. Resistance to
clarithromycin appears to increase in children over time in
some European countries, possibly because of the use of
macrolides to treat respiratory tract infections.11 12 In the US,
a high resistance rate for clarithromycin in the children
infected with H pylori was reported and would explain the
high failure rate of clarithromycin based triple treatment.13 14
However, most publications are from single centres or include
only a small number of children.
In 1996, a European Paediatric Task Force was founded
including paediatric gastroenterologists as well as microbiol-
ogists and epidemiologists from different European coun-
tries. A consensus report,15 and several multicentric studies
on diagnostic or therapeutic issues in paediatric H pylori
infection have been published16 17 or are currently underway.
In 1998, a databank was created, in which our group
members participated. The aim of the present study was to
assess the primary and secondary antibiotic resistance of H
pylori strains obtained from children living in Europe over a 4-
year period. Other aims were to identify risk factors for H
pylori resistance against amoxicillin, clarithromycin, metro-
nidazole and double resistance against clarithromycin plus
metronidazole before the first treatment.
PATIENTS AND METHODS
Study centres and inclusion criteria
Members of the European Paediatric Task Force for H pylori
infection were asked to submit data on consecutive patients
(18 years of age with a positive culture and who had
undergone antibiotic susceptibility testing. Seventeen centres
from 14 different European countries participated: three
Scandinavian countries (Finland, Sweden and Denmark)
combined as Northern Europe, three Eastern European
countries from the former East block (Poland, Hungary and
Croatia), four countries from Southern Europe (Greece, Italy,
Spain and Portugal) and four from Western Europe (Belgium,
France, Germany and Austria). The ethics committee of the
Abbreviation: MIC, minimal inhibitory concentration
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University of Munich approved the protocol for the anonymous
data collection and analysis.
Questionnaire
The study centres provided the following items on a
standardised questionnaire: age, sex, country at the time of
endoscopy (country of study centre), country of birth of the
child and the mother, the presence of gastric or duodenal
peptic ulcer disease upon endoscopy and whether the child
had ever received treatment for H pylori infection in the past.
Bacterial culturing and antibiotic susceptibility testing
Cultures for H pylori and antibiotic susceptibility testing for
metronidazole, clarithromycin and amoxicillin were carried
out at the local sites. Minimal inhibitory concentration (MIC)
breakpoints for resistance were defined as follows: metroni-
dazole .8 mg/ml; clarithromycin >1.0 mg/ml; amoxicillin
>0.5 mg/ml. Most centres used the epsilometer test (E test),
but in three centres the agar diffusion technique was
followed. A patient was considered to harbour a double
resistant strain if testing for metronidazole and clarithromy-
cin gave results above the given breakpoints.
Statistical analysis
Statistical analysis was carried out using STATA 7.0 statistical
software (Strata Corporation, Texas, USA, 1997). The
distribution of resistance to metronidazole or clarithromycin,
and of the presence of ulcer was compared in different strata
of variables. A univariate analysis was carried out on all of
the patients with no missing values for all of the factors
considered. The odds were calculated for the resistance to
metronidazole, clarithromycin, metronidazole plus clarithro-
mycin (double resistance) and for the presence of peptic
ulcer. All variables significantly associated with the studied
event (p(0.25) were included in a multiple logistic regres-
sion model. All models were adjusted for sex and age, as a
variable divided into three age groups. All variables asso-
ciated with resistance or the presence of peptic ulcer were
gathered into a final model. The multivariate analysis was
carried out by a logistic regression, using a backward
elimination procedure of variables not significantly asso-
ciated with resistance or the presence of an ulcer (p(0.05).
Estimated odds ratio (OR) and 95% confidence intervals
(95% CI) were calculated. Interaction and confusion were
tested among all of the variables included in the final model.
For each calculation, two populations were considered and
two multiple logistic regression analyses conducted. The first
one included only the patients having no missing values for
the factors included in the multivariate analysis, whereas the
second one considered exactly the same population as in the
univariate analysis. The aim of the first analysis was to use as
many patients as possible, whereas the second analysis
simplified the presentation of the results with the same
samples as in the univariate analysis. As no major differences
were noted between the two models, only the last one is
reported in the results section.
RESULTS
Between January 1999 and December 2002, a total of 1233
patients were included in the database; 46.7% were males,
13% were,6 years of age, while equal proportions comprised
the other two age groups (6–12 years: 43% and .12 years:
44%). The majority (n = 1037) were tested for upper
abdominal symptoms before any specific treatment for H
pylori infection (group A) was given, while 196 children were
tested after, at least one failed treatment. There was a slight,
but not significant decrease in registered patients over the 4-
year period. The country of birth was outside Europe for
14.6% of the children, but for 41.3% of the mothers,
indicating the high percentage of immigrants, particularly
from Africa and the Middle East.
Table 1 gives the absolute numbers of the patients and
their characteristics, including the results of susceptibility
testing for the total study group, and the two subgroups,
group A without and group B with previous anti-H pylori
treatment.
Antibiotic resistance before the first treatment
(group A)
Amoxicil l in
Resistance to amoxicillin was a rare event (6/1037, 0.6%),
with 2 patients reported from Greece, and one each from
Croatia, Italy, Finland and Poland.
Clarithromycin
Resistance to clarithromycin was detected in 20% of the
strains (199/991) obtained before the first treatment. In the
univariate analysis, important risk factors were: age
,6 years, male sex, living in Southern Europe and country
of birth of the child and his/her mother in Western or
Southern Europe (table 2). The final logistic regression model
showed a 2.25 times higher risk for primary clarithromycin
resistance, if the child grew up in Southern Europe
(p,0.001). Young age and male sex remained independent
major risk factors (table 3).
Metronidazole
Primary resistance to metronidazole was found in 23% of the
strains (233/1024). In the univariate analysis, only two
factors were found to be of considerable risk for primary
resistant to metronidazole: country of birth of the child and
the mother (table 4). Multilogistic regression models showed
that patients born in Asia, Africa or Middle East had a 2.4
times higher risk (95% CI 1.61 to 3.66) of being infected with
a metronidazole resistant strain than patients of equal age
and sex born in Western, Northern or Southern Europe
(p,0.001; table 5). No interaction was found between the
different variables in the final model.
Double resistance
A primary resistance against both clarithromycin and
metronidazole was found in 53 of 992 (5.3%) strains. No
significant risk factors could be identified, except that in 2001
fewer children were diagnosed with a double resistant strain.
Antibiotic resistance after at least one failed
treatment (group B)
When patients with treatment failure were compared with
untreated children (before the first treatment), no difference
was identified in the factors assessed except for antibiotic
resistance. The chance to harbour a resistant strain sig-
nificantly increased after failed treatment, for clarithromycin
from 20% to 42% (p,0.001), for metronidazole from 23% to
35% (p = 0.001), and for resistance to both from 5.3% to
15.3% (p,0.001), although the amoxicillin resistance rate
remained the same (0.6%; table 1). No other identified risk
factor was linked to secondary antibiotic resistance.
Peptic ulcer disease
Peptic ulcer disease was diagnosed in 6.8% of the children
(80/1180), with no difference between untreated children
(before first treatment) or after treatment failure (table 1).
No relation was found between antibiotic susceptibility and
peptic ulcer disease. The only significant risk factor linked to
peptic ulcer disease was age. Patients with peptic ulcer
disease were significantly older (12.5 years, 95% CI 11.8 to
13.2) compared with patients with gastritis only (10.9 years
95% CI 10.6 to 11.1; p = 0.001). The rate of peptic ulcer
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disease was low in children ,6 years of age (3.5%, 4/118),
and between 6 and 11 years of age (4.6%, 17/390); it
increased to 10.4% in patients older than 11 years. The final
logistic regression model showed an adjusted OR of 3.10
(1.07 to 8.95) for children .11 years compared with the
youngest age group (p = 0.036) of the same sex.
DISCUSSION
Antibiotic resistance in H pylori is a serious public health
problem, because about 10–15% of infected people develop
severe complications in adult life like peptic ulcer disease and
gastric malignancies, and only cure of the infection prevents
these sequelae. Large numbers of cases are needed to obtain
reliable results for the prevalence rate of antibiotic resistance.
Such studies have been carried out on H pylori strains isolated
from adults in Europe (n = 1274)18 and the US (n = 347).19
However, such investigations have never been conducted on
a sufficient number of children despite the fact that the
context of prescribing antibiotics is different.
The main aim of our study was to obtain reliable data by
including a large number of previously untreated and
unselected H pylori infected children. To avoid any selection
and reporting bias, every child with a successful susceptibility
testing was included. The contributing centres conducted
culture tests for H pylori as part of the routine work up during
upper endoscopy with a success rate for culture of .80%, as
previously shown.17 Although the participating centres were
mostly University hospitals, a selection bias for children with
a higher likelihood for a primary antibiotic resistance rate is
unlikely. Most patients in this study were referred for the
procedure from the caring doctor because of upper abdominal
pain, some with a positive non-invasive diagnostic test
indicating H pylori infection.
The multicentric character of our study caused several
limitations. There was an uneven distribution of patients
from the different countries, with fewer patients from
Scandinavia. The results of the different countries were
analysed separately, and thereafter in groups according to
their geographical region. Countries from the former East
block were combined, because in these countries the
availability of expensive antibiotics, like second-generation
macrolides, may be different and could influence the
antibiotic resistance pattern.
Owing to logistic and financial constraints, cultures and
antibiotic susceptibility testing were not carried out in a
central bacteriology laboratory, as was the case in the
European and North American studies on adults.18 19 Two
different methods were used for susceptibility testing: E test
Table 1 Sex, age, country of residence, country of birth of the child and the mother, year and results of antibiotic susceptibility
testing (n = 1233)
Factors Description
All patients
(n = 1233)
Group A
before treatment
(n = 1037)
Group B after
treatment failed
(n = 196)
Sex, n = 1197 Male 559 465 94
Female 638 542 96
Age (years), n = 1232 ,6 162 137 25
6–11 531 448 83
>12 539 452 87
Country of residence, n = 1024 Northern Europe 43 34 9
Southern Europe 222 192 30
Eastern Europe 107 88 19
Western Europe 861 723 138
Country of birth, n = 1108 Northern Europe 29 22 7
Southern Europe 224 196 28
Eastern Europe 172 139 33
Western Europe 521 426 95
Asia, Africa, America and
Middle East
162 147 15
Mother’s country of birth, n = 1070 Northern Europe 15 13 2
Southern Europe 214 187 27
Eastern Europe 187 150 37
Western Europe 212 183 29
Asia, Africa, America and
Middle East
442 365 77
Diagnostic year, n = 1233 1999 371 316 55
2000 298 255 43
2001 299 245 54
2002 265 221 44
Peptic ulcer, n = 1180 No 1100 930 170
Yes 80 68 12
Metronidazole resistance, n = 1216 Susceptible 916 791 125
Resistant 300 233 67
Clarithromycin resistance, n = 1181 Susceptible 903 792 111
Resistant 278 199 79
Amoxicillin resistance, n = 1094 Susceptible 1087 923 164
Resistant 7 6 1
Metronidazole and clarithromycin
resistance, n = 1181
Metro and clari susceptible 1099 939 160
Metro and clari resistant 82 53 29
Metro, Clari and Amox resistance,
n = 1146 Metro/clari and amox susceptible 647 579 68
Only metro resistant 216 179 37
Only clari resistant 196 146 50
Only amox resistant 3 3 0
Metro and clari resistant 80 51 29
Metro and amox resistant 2 1 1
Clari and amox resistant 0 0 0
Metro and clari and amox resistant 2 2 0
Antibiotic resistance of H pylori in children 1713
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and agar diffusion. For clarithromycin, a perfect correlation
was shown when these two methods were compared on the
same isolates.20 However, differences were observed with
respect to metronidazole because there is a continuum of
MICs rather that a double population. In this study, MIC
values were reported from 852 isolates. As expected, the
distribution curve showed a much better separation between
positive and negative results for clarithromycin compared
with metronidazole. Only 31 (3.6%) patients harboured
isolates with MIC values for clarithromycin within 4 dilutions
of the cut off value (MIC range 0.25–2.0), whereas this was
the case in 73 (8.6%) patients for metronidazole (MIC range
4.0–32). Therefore, differences between the laboratories
probably had only a minor effect on the resistance rates,
particularly for clarithromycin.
In contrast with the European multicentre study on
adults,18 reliable information was obtained with respect to
previous anti-H pylori treatment. Parents tended to have
reasonable recall of whether or not their child had been
treated for the infection. However, they often did not
remember the names of the antibiotics the child had taken
in the past. Therefore, the term primary resistance applies to
the absence of any previous specific anti-H pylori treatment,
and not to any previous intake of amoxicillin, clarithromycin
and metronidazole. In the US data base, previous treatment
was recorded, but pre-treatment resistance rates were not
calculated.19 However, this information is essential for the
surveillance of primary resistance and to give guidelines for
first line treatment.
The primary resistance rate of isolates from children was
20% for clarithromycin and 23% for metronidazole. No
representative data for comparison with adults living in
Europe are available in the literature. The results of the
European multicentre survey represents 17 European coun-
tries, but did not distinguish between isolates from patients
before or after failed treatment.18
By contrast, the European MACH2 study recruited most
patients from Northern and Western Europe.20 Therefore, we
could only compare results of primary resistance from 515
adults in Germany during the years 1999 and 200021 with the
results obtained in our study from children living in Germany
(before treatment n = 201). The resistance rate for clarithro-
mycin was markedly lower in adults than in children (2.7% v
15.9%). By contrast, for metronidazole the resistance rates
were very similar in adults and children (25% v 27.5%).
The presence of a resistant strain may indicate the
transmission of a resistant strain or in vivo selection of
resistance. The similar rate of metronidazole resistance in
children and adults is in favour of the transmission of a
resistant strain to the children. Children acquire the H pylori
Table 2 Univariate analysis of factors associated with metronidazole resistance among paediatric patients not previously
treated for Helicobacter pylori infection (n = 831)
Factors Description
Metronidazole
OR 95% CI p Value
susceptible
n = 635
Resistant
n = 196
Sex Male 283 91 1
Female 352 105 0.93 (0.67 to 1.28) 0.647
Age (years) ,6 90 24 1
6–11 280 87 1.17 (0.70 to 1.94) 0.557
.11 265 85 1.20 (0.72 to 2.01) 0.480
Country of birth Western Europe 457 117 1
Eastern Europe 98 29 1.16 (0.73 to 1.83) 0.538
Asia, Africa, America and
Middle East
80 50 2.44 (1.62 to 3.67) ,1023
Mother’s country of birth Western Europe 281 72 1
Eastern Europe 111 33 1.16 (0.73 to 1.85) 0.533
Asia, Africa, America and
Middle East
243 91 1.46 (1.03 to 2.08) 0.035
Country of residence Northern Europe 23 7 1
Southern Europe 143 41 0.94 (0.38 to 2.35) 0.898
Eastern Europe 64 20 1.03 (0.38 to 2.75) 0.958
Western Europe 405 128 1.04 (0.44 to 2.48) 0.932
Date of investigation 1999 176 55 1
2000 157 53 1.08 (0.70 to 1.67) 0.728
2001 167 44 0.84 (0.54 to 1.32) 0.457
2002 135 44 1.04 (0.66 to 1.64) 0.856
Peptic ulcer No 596 185 1
Yes 39 11 0.91 (0.46 to 1.81) 0.785
CI, confidence interval; OR, odds ratio.
p Value obtained by a univariate logistic model.
Table 3 Final logistic regression model for metronidazole resistance among patients not
previously treated for Helicobacter pylori infection and no missing data for all of the
factors considered in the univariate analysis (n = 831)
Unadjusted
OR
Adjusted
OR 95% CI p Value
Sex (women v men) 0.93 0.92 (0.66 to 1.28) 0.620
Age (v ,6 years)
6–11 1.17 1.09 (0.65 to 1.83) 0.739
.11 1.20 1.09 (0.64 to 1.85) 0.751
Country of birth (v Western Europe)
Eastern Europe 1.16 1.15 (0.72 to 1.84) 0.557
Asia, Africa, America and Middle East 2.44 2.42 (1.61 to 3.66) ,1023
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infection mainly from their infected parents, mostly their
mother, in both industrialised and developing countries.22 In
this study, the only risk factor for primary metronidazole
resistance was the immigration from a non-European
country. Metronidazole is widely used in Africa and Asia to
treat parasitic diseases and gynaecological infections.
Therefore, in these countries female adults have a higher
risk of being exposed to this antibiotic agent.
By contrast, the higher primary clarithromycin resistance
rate in isolates from children compared with adults points to
an in vivo acquisition of the resistance during childhood.
Macrolide resistance is based on defined point mutations in
the peptidytransferase loop in both copies of the 23S rRNA
gene. Monotherapy with clarithromycin induces these muta-
tions in up to 21% of patients infected with a susceptible H
pylori strain.23 Clarithromycin has been used increasingly over
the last 10 years to treat upper respiratory tract infection in
children. Owing to the high price, the newer macrolides have
been less frequently prescribed in countries of the former
Eastern block, as well as in Africa and Asia. In fact, children
born in these countries harboured considerably less clari-
thromycin resistant H pylori strains than children from
countries with a high consumption of macrolides, such as
Italy, Spain and Portugal. Other independent risk factors—
young age and male sex—which were identified in the
multilogistic regression analysis, also pointed to an in vivo
acquisition of clarithromycin resistance in our patients.
Younger compared with older children, and boys compared
with girls, suffer more often from infectious diseases,
particularly respiratory tract infections and therefore, are
more likely to be exposed to the new macrolides. Our findings
confirm a previous report in H pylori infected Spanish
children, which showed a decreasing prevalence of clari-
thromycin resistance with age: 45.4%, 30.2% and 9.5% in the
age groups 4–8 years, 9–13 years, and 14–18 years, respec-
tively.24 In Portugal, a higher clarithromycin resistance rate
was also reported in children (44.8%) compared with adults
(14.8%).25
Peptic ulcer disease was a rare finding, with ,5% in
children ,12 years of age. This rate increased to .10% in
teenagers. Older age was the only risk factor for this
complication. This could be due to the longer duration of
the infection itself, but more likely, other risk factors may
contribute in teenagers—for example, smoking, consumption
of alcohol and ulcerogenic drugs. The low prevalence of
peptic ulcer disease in symptomatic children referred for
upper endoscopy has implications on the ‘‘test and treat’’
strategy. In a paediatric population with a prevalence of 10%
for H pylori infection, 100 symptomatic teenagers need to be
investigated by a reliable non-invasive diagnostic test, and 10
Table 4 Univariate analysis of factors associated with clarithromycin resistance among paediatric patients not previously
treated for Helicobacter pylori infection (n = 800)
Clarithromycin
OR 95% CI p Value
Susceptible
n = 633
Resistant
n = 167
Sex Female 364 76 1
Male 269 91 1.62 (1.15 to 2.82) 0.006
Age (years) .11 275 56 1
6–11 278 78 1.38 (0.94 to 2.02) 0.100
,6 80 33 2.03 (1.23 to 3.33) 0.005
Country of birth Western Europe 437 134 1
Eastern Europe 88 14 0.52 (0.29 to 0.94) 0.031
Asia, Africa, America and
Middle East
108 19 0.57 (0.34 to 0.97) 0.038
Mother’s country of birth Western Europe 258 94 1
Eastern Europe 98 19 0.53 (0.31 to 0.92) 0.023
Asia, Africa, America and
Middle East
277 54 0.54 (0.37 to 0.78) 0.001
Country of residence Northern Europe 30 1 (3.3%) 1
Southern Europe 122 59 (32.5%) 14.51 (1.93 to 108.98) 0.009
Eastern Europe 47 10 (17.5%) 6.38 (0.78 to 52.44) 0.085
Western Europe 434 97 (18.2%) 6.71 (0.90 to 49.77) 0.063
Country of residence Northern, Eastern and Western
Europe
511 108 (17.4) 1
Southern Europe 122 59 (32.5%) 2.29 (1.57 to 3.33) ,1023
Date of investigation (1999 178 45 1
2000 146 48 1.30 (0.82 to 2.06) 0.265
2001 161 44 1.08 (0.68 to 1.72) 0.744
>2002 148 30 0.80 (0.48 to 1.34) 0.397
Peptic ulcer No 589 161 1
Yes 44 6 0.50 (0.21 to 1.19) 0.117
p Value obtained by a univariate logistic model.
Table 5 Final logistic regression model for clarithromycin resistance among patients not
previously treated for Helicobacter pylori infection (n = 800)
Unadjusted. OR Adjusted OR 95% CI p Value
Sex (men v women) 1.62 1.58 [1.12 to 2.24] 0.010
Age (v .11) years.
6–11 1.38 1.21 (0.81 to 1.78) 0.350
6 2.03 1.82 (1.10 to 3.03) 0.020
Country of residence (Southern Europe v
Northern and Eastern and Western)
2.29 2.25 (1.53 to 3.30) ,1023
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treated with triple treatment, in order for one with peptic
ulcer disease to benefit. In children ,12 years of age, .200
children need to be screened for one child with H pylori
related peptic ulcer disease to benefit. In a population with a
lower prevalence of H pylori infection like in most Northern
and Western European countries, the cost/benefit ratio would
be even lower.
Our results from more than a thousand H pylori infected
children before their first treatment have major implications
for the first line treatment. Despite the fact that metronida-
zole has a lower effect on the clinical efficacy of metronida-
zole-based triple treatment, when the metronidazole
resistance rate reaches 40%, as is the case in children born
in Africa, Asia or the Middle East, this antibiotic should not
be used. Clarithromycin-based triple treatment cannot be
recommended without previous susceptibility testing in
children living in Southern Europe, where a third of the
children are infected with a macrolide resistant strain. Even
in Western and Eastern European countries, susceptibility
testing should be conducted whenever possible, to obtain a
high primary cure rate. This is particularly important in
children ,12 years of age, for whom no rescue treatment is
currently available.
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